First total synthesis of Combretastatin D-2 congeners named Isocorniculatolide A and 11-o-methylisocornicultolide
Poster Jun 07, 2012
Vijaya Kumar.Tulam, Subhash Chandra Bose. Kotte, Sanjay Kumar. Hirasker, Prathama S Mainkar, P.M. Murali and K. Mukkanti.
First total synthesis of newly isolated natural products Isocorniculatolide A and 11-o-methylisocornicultolide A was accomplished. Commercially available 3, 4 dihydroxy benzaldehyde was selectively protected at the 4- position followed by the Wittig elongation to afford α, β unsaturated ester which was subsequently treated with DIBAL to afford (E)-2-(benzyloxy)-5-(3-hydroxyprop-1-enyl) phenol and then finally coupled this intermediate with 3-(4-bromophenyl) propanoic acid to achieve (Z)-3-(4-(benzyloxy)-3-hydroxyphenyl) allyl 3-(4-bromophenyl) propanoate. Finally macro cyclization using Ullmann ether synthesis and then treatment with Pd/C accomplished Isocorculatolide A. In the same way we achieved 11-o-methylisocornicultolide starting from Isovanillin.
Touching BACE. How Inhibiting β-Amyloid Production by Steric Hindrance with a Novel Immunotherapy Improves Memory in PDAPP MicePoster
The work presented in this poster aims to assess whether intracerebroventricular (ICV) administration of 2B3 alleviated age dependent memory deficits in PDAPP mice and to determine whether 2B3 altered APP metabolism and NMDA receptor phosphorylation ex vivo.READ MORE
Multiplexed Cell- and Bead-based Assays in a No-wash Format for Biologics Screening and CharacterizationPoster
Here we present the results generated from multiplexed no-wash protocols using TTP Labtech’s mirrorball, a laser scanning cytometer.READ MORE
Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy TargetsPoster
Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.
Comments | 0 ADD COMMENT
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
News Jan 12, 2017